RABANY CLAYBORN: Open Payments
NPI 1003163460 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,038 in 42 payments from 14 companies in 2025. Trend: 2023 $221 · 2024 $667 · 2025 $1,038
Food & beverage: $1,038
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $287 |
| Otsuka America Pharmaceutical, Inc. | 8 | $206 |
| Alkermes, Inc. | 3 | $85 |
| Vanda Pharmaceuticals Inc. | 4 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $76 |
| Astellas Pharma US Inc | 2 | $55 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
Products named: VRAYLAR, ABILIFY MAINTENA, ARISTADA, FANAPT, COBENFY, Veozah, AIRSUPRA, ZENPEP.
Industry payments across WI — which companies pay providers there.
